Samso News: Echo IQ Limited — FDA 510(k) Submission Lodged Following Mayo Clinic Validation - Catalyst for Market Acceptance ? - Time to get On Board the EIQ Train
- Noel Ong
- Jan 30
- 7 min read
Announcement
1. Exceptional Results from Validation Study for EchoSolv HF- 24 November 2025 (view the announcement)
2. Formal lodgement of FDA submission for EchoSolv HF - 15 December 2025 (view the announcement)
As we release this Samso News on EIQ, the market has taken a liking to the recent news. Samso has been following the Echo IQ Limited story as it advances AI-based clinical decision support tools through formal regulatory pathways.
This update reflects news across two key steps: independent clinical validation and formal FDA submission. I have now understood that a submission to the FDA is done with a great level of confidence that all the boxes have been ticked and approval is on the higher chance of success.
Together, these milestones move the Company from development into the regulatory review phase, which is a recognised inflection point for medical technology businesses targeting the US market.
Echo IQ Limited – EchoSolv HF and the Path to US Market Entry
Echo IQ Limited (ASX: EIQ) is an Australian AI and medical technology company focused on improving decision-making in cardiology. Its lead product, EchoSolv HF, is a heart failure clinical decision support software designed to assist clinicians in detecting heart failure using echocardiogram data. The Company’s recent announcements outline the completion of clinical validation with the Mayo Clinic Platform and the subsequent formal lodgement of an FDA 510(k) submission in the United States.
Highlights – Clinical Validation Milestone | 24 November 2025
Echo IQ announced the successful completion of a clinical validation study for EchoSolv HF in collaboration with the Mayo Clinic Platform’s Validate program, marking the final clinical requirement before FDA submission.
The validation study assessed EchoSolv HF on an independent dataset of approximately 17,000 patient echocardiograms sourced from the Mayo Clinic Platform.
EchoSolv HF met its primary endpoint, delivering a sensitivity of 99.5% in identifying heart failure cases and a specificity of 91.0% in identifying non-heart failure cases.
The Mayo Clinic Platform’s Validate program provides an independent, objective assessment of AI performance, accuracy, and susceptibility to bias.
Completion of this study represented the final clinical step required before advancing to a formal FDA 510(k) submission.
The Company confirmed that the FDA submission process was being finalised, with lodgement expected in the coming weeks.
Management highlighted that potential FDA clearance would enable EchoSolv HF to be marketed in the US, where heart failure accounts for 17% of healthcare expenditure and represents a US$60 billion total addressable market.
Highlights – FDA 510(k) Submission Lodged | 15 December 2025
Echo IQ confirmed the formal lodgement of its FDA 510(k) premarket notification for EchoSolv HF, advancing the product into the regulatory review phase in the United States.
The FDA submission incorporates results from the completed Mayo Clinic Platform validation study, including performance data from the 17,000-echo dataset.
EchoSolv HF demonstrated 99.5% sensitivity and 91.0% specificity, supporting claims of substantial equivalence under the FDA’s 510(k) framework.
FDA clearance, if obtained, would allow EchoSolv HF to be marketed and distributed in the US for its cleared indications for use.
The Company reiterated that only around 50% of heart failure cases are currently accurately diagnosed, highlighting the clinical need for improved decision support tools.
Heart failure is described as the leading cause of rehospitalisation in the US and is estimated to affect one in four Americans over their lifetime.
Echo IQ noted that FDA clearance would unlock a significant commercial opportunity within the US healthcare system, which accounts for 17% of national healthcare spending.
Leadership Commentary
Chief Executive Officer, Mr Dustin Haines, commented:
“We are pleased to have completed the formal submission process for EchoSolv HF via the FDA’s 510(k) clearance pathway. The lodgement of the submission is a testament to the hard work and disciplined execution of Echo IQ’s operations team alongside our key industry partners including Mayo Clinic.”
“With the submission process complete, we will continue to work with our broad network of industry partners across both product development and distribution, ahead of an expected FDA decision in the coming months. The ongoing advancement of our healthcare technology suite positions the Company for another momentum driven year ahead, leveraging our proprietary technology to deliver improved healthcare solutions, and we look forward to updating our investors on key progress initiatives early in the new year.”
Near-term Milestones to Watch
FDA review process for the EchoSolv HF 510(k) submission
Regulatory feedback or requests for additional information from the FDA
Potential FDA clearance decision
Continued engagement with US healthcare and distribution partners ahead of commercial rollout
Samso Concluding Comments
The November and December announcements together outline the path toward US market access for EchoSolv HF. Clinical validation with the Mayo Clinic Platform addressed the final technical requirement before regulatory submission.
The December lodgement confirms that Echo IQ has moved into the FDA review phase, which is a critical step for any medical technology seeking US commercialisation. The process is governed by defined regulatory standards and timelines, which remain outside the Company’s control.
Heart failure represents a large and well-documented healthcare burden in the US, and Echo IQ’s disclosures consistently reference underdiagnosis as a key problem the software aims to address. However, regulatory clearance is required before any commercial claims can be realised.
From an investor perspective, attention now shifts away from development milestones toward regulatory outcomes and execution readiness. The next phase will be shaped by FDA engagement, clearance timing, and the Company’s ability to translate approval into market uptake.
Market Implication - The Investor Lens
AS we write this Samso News, the market capitalisation of EIQ is now approaching AUD $305M, and the share price is doing the vertical dance (Figure 1), which would be pleasing to all shareholders. When we released the first Coffee with Samso with EIQ (Coffee with Samso - An AI Solution to a Cardiovascular Problem | EchoIQ Limited (ASX: EIQ), the share price was around the AUD $0.17 mark, and as of the 23rd January 2026, that is at AUD $0.52, which would relate to a rise of 3X in value.
This is a great outcome for management, and I would assume that the journey ahead is looking bright. Dustin Haines, who is the CEO of EIQ, was very optimistic about this outcome, and I am sure he will be eagerly awaiting to update the market with pending news.
Figure 1: EIQ share price chart as of 23rd January 2026. (source: CommSec)
Is this a bad time for investors to get in on the story? Now, if one looks at the potential market value, the simple answer is yes. A market capitalisation of AUD $300M is going to look cheap when you compare it with the ASX companies like ResMed and Mesoblast, in which I was an investor in the early stages. Racura Oncology, which we covered on Samso News before they went on a 4-time multiple recently, is another reason for readers to do some serious DYOR.
The Samso Way – Seek the Research
Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Never bite off more than you can chew is my parting comment.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Comments